New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmapheresis

Front Matter....Pages i-viii
Protein Catabolic Factors in Patients on Renal Replacement Therapy....Pages 1-9
β 2 Microglobulin-Derived Amyloid in Dialysis Patients....Pages 11-18
Mechanisms and Consequences of Complement Activation During Hemodialysis....Pages 19-26
Neutrophil Activation During Hemodialysis....Pages 27-37
Biocompatibility — A System Approach....Pages 39-52
Treatment of Uraemic Anaemia with Recombinant Human Erythropoietin....Pages 53-59
Endocrine Abnormalities in Patients with Endstage Renal Failure....Pages 61-67
Carnitine Supplementation in Uremia....Pages 69-77
Pathophysiology and Treatment of Hypertension in Dialysis Patients....Pages 79-91
Adjustment of Drug Dosage to Hemodialysis Patients....Pages 93-103
Pharmacokinetic Aspects of Drug Transport in Continuous Ambulatory Peritoneal Dialysis....Pages 105-116
Drug Therapy During Continuous Arteriovenous Hemofiltration....Pages 117-127
The Biology of the Peritoneal Membrane During Chronic Peritoneal Dialysis....Pages 129-133
Lymphatic Absorption During Peritoneal Dialysis....Pages 135-138
CAPD with Bicarbonate Solution....Pages 139-147
Glucose Polymer as an Osmotic Agent in CAPD....Pages 149-156
Effects of Long-Term Treatment with Human Recombinant Erythropoietin in Patients on CAPD....Pages 157-165
Continuous Arterio-Venous Hemofiltration: Optimization of Technical Procedures and New Directions....Pages 167-179
Is Continuous Haemofiltration Superior to Intermittent Dialysis and Haemofiltration Treatment?....Pages 181-192
Therapeutic Apheresis Update....Pages 193-201
Treatment Combining Plasmapheresis and Pulse Cyclophosphamide in Severe Systemic Lupus Erythematosus....Pages 203-213
Back Matter....Pages 215-218